MMP-1 Antisense Oligonucleotides, Olipass, Published Apr 15

The European Patent Office has published patent application EP3794124A1 for matrix metalloproteinase-1 (MMP-1) antisense oligonucleotides filed by Olipass Corporation. This A1 publication indicates the application has completed the European search report phase and is now publicly available for opposition purposes. The application covers antisense oligonucleotides targeting MMP-1 expression for therapeutic use, classified under A61P 17/00 (dermatological conditions) and A61Q 19/08 (anti-aging skincare).

For pharmaceutical and biotechnology companies developing antisense oligonucleotide therapeutics, this publication establishes prior art as of the priority date. Competitors in the MMP-1 inhibition space should review the claims to assess freedom-to-operate implications. The 31 designated contracting states provide geographic scope for potential patent protection across major European markets including Germany, France, and the United Kingdom.